Marshall Wace
FOLD

Marshall Wace’s Amicus Therapeutics FOLD Stock Holding History

Marshall Wace’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.49M Buy
518,008
+277,108
+115% +$3.97M 0.01% 1107
2025
Q4 		$3.43M Buy
+240,900
New +$2.37M ﹤0.01% 1326
2025
Q3 		– Sell
-15,062
Closed -$86.3K – 3040
2025
Q2 		$86.3K Sell
15,062
-181,051
-92% -$1.17M ﹤0.01% 2559
2025
Q1 		$1.6M Buy
196,113
+123,145
+169% +$1.14M ﹤0.01% 1564
2024
Q4 		$687K Buy
72,968
+52,368
+254% +$544K ﹤0.01% 1904
2024
Q3 		$220K Buy
+20,600
New +$224K ﹤0.01% 2265
2023
Q4 		– Sell
-62,114
Closed -$755K – 2310
2023
Q3 		$755K Buy
+62,114
New +$801K ﹤0.01% 1585
2021
Q3 		– Sell
-16,945
Closed -$163K – 3148
2021
Q2 		$163K Buy
+16,945
New +$165K ﹤0.01% 2483
2021
Q1 		– Sell
-47,199
Closed -$1.09M – 2598
2020
Q4 		$1.09M Buy
+47,199
New +$965K 0.01% 1179
2019
Q3 		– Sell
-742,236
Closed -$9.26M – 1755
2019
Q2 		$9.26M Buy
742,236
+573,235
+339% +$7.27M 0.08% 303
2019
Q1 		$2.3M Buy
169,001
+10,911
+7% +$133K 0.02% 700
2018
Q4 		$1.51M Sell
158,090
-1,007,851
-86% -$11.1M 0.02% 797
2018
Q3 		$14.1M Buy
+1,165,941
New +$16.3M 0.12% 227
2016
Q3 		– Sell
-64,107
Closed -$350K – 1004
2016
Q2 		$350K Buy
+64,107
New +$448K ﹤0.01% 880
2015
Q4 		– Sell
-42,224
Closed -$591K – 1018
2015
Q3 		$591K Sell
42,224
-283,044
-87% -$4.44M 0.01% 713
2015
Q2 		$4.6M Sell
325,268
-870,246
-73% -$10.5M 0.06% 312
2015
Q1 		$13M Sell
1,195,514
-73,715
-6% -$650K 0.17% 155
2014
Q4 		$10.6M Buy
+1,269,229
New +$8.71M 0.14% 186
2014
Q3 		– Sell
-339,443
Closed -$1.13M – 928
2014
Q2 		$1.13M Buy
+339,443
New +$797K 0.02% 488

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Marshall Wace's FOLD Position: Q1 2026 in Review

Marshall Wace increased its Amicus Therapeutics (FOLD) stake by 115% in Q1 2026, buying an estimated $3.97M and bringing the position to 518,008 shares worth $7.49M. The position accounts for 0.01% of the portfolio, ranked #1107.

Marshall Wace first reported a position in FOLD in Q2 2014 and has held it in 19 quarters since. The position peaked at $14.1M in Q3 2018. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Marshall Wace held 518,008 shares of Amicus Therapeutics worth $7.49M as of Q1 2026.
  • Marshall Wace bought 277,108 Amicus Therapeutics shares in Q1 2026, an estimated $3.97M.
  • Amicus Therapeutics made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1107 holding.
  • Marshall Wace first reported a position in Amicus Therapeutics in Q2 2014 and has held it in 19 quarters since.
  • Marshall Wace's Amicus Therapeutics position peaked at $14.1M in Q3 2018.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.